A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AR19, a Manipulation-Resistant Formulation of Amphetamine Sulfate, in Adults With Attention-Deficit/Hyperactivity Disorder
Stephen V. Faraone(FDI World Dental Federation), Joel Young(Dalhousie University), C. Brendan Montano, Valerie Arnold(Memphis Health Center), Steve Caras(Arbor Pharmaceuticals (United States)), Elias Sarkis, Andrew J. Cutler(Meridien Research), Ann Childress(Center for Psychiatry and Behavioral Medicine)
Cited by 3
Related Papers
The Prevalence and Correlates of Adult ADHD in the United States: Results From the National Comorbidity Survey Replication
|American Journal of Psychiatry|2006|2.9k
The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies
|Psychological Medicine|2005|2.3k
Attention-deficit hyperactivity disorder
|The Lancet|2005|1.5k
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder
|Neuroscience & Biobehavioral Reviews|2021|1.4k
Attention-deficit/hyperactivity disorder
|Nature Reviews Disease Primers|2015|1.3k